Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Week-by-week dosage comparison Weight loss comparison at matched timepoints *Tirzepatide 24 and 48-week figures estimated from SURMOUNT-1 trajectory data, as primary endpoint was 72 weeks
Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema
tirzepatide (Zepbound) about 21% in SURMOUNT-1
Association Between Semaglutide Use and Risk of Back Pain in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Research and Clinical Practice, vol
Singh founded Apex Mens Health Clinic after recognizing that many men were not receiving the research-backed, results-driven treatments they deserve
This article provides an informational overview of BPC-157 and TB-500, explains why they are often discussed together, and outlines how medical providers may assess their use on a case-by-case basis
US$ 24.87
US$ 27.62
